Show simple item record

dc.contributor.authorTristán Manzano, María 
dc.contributor.authorJusticia Lirio, Pedro
dc.contributor.authorMaldonado Pérez, Noelia
dc.contributor.authorCortijo Gutiérrez, Marina
dc.contributor.authorBenabdellah, Karim
dc.contributor.authorMartín, Francisco
dc.date.accessioned2020-11-04T11:50:08Z
dc.date.available2020-11-04T11:50:08Z
dc.date.issued2020-09-04
dc.identifier.citationTristán-Manzano, M., Justicia-Lirio, P., Maldonado-Pérez, N., Cortijo-Gutiérrez, M., Benabdellah, K., & Martin, F. (2020). Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 11. [doi: 10.3389/fimmu.2020.02044]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/64049
dc.descriptionWe thank GENYO Institute and LentiStem Biotech for the support to compile of the necessary information to write this review. We also thank Fundación Poco Frecuente (FPF) and Asociación Española de Enfermos con Glucogenosis (AEEG) for their kindly support.es_ES
dc.description.abstractImmunotherapy is a very promising therapeutic approach against cancer that is particularly effective when combined with gene therapy. Immuno-gene therapy approaches have led to the approval of four advanced therapy medicinal products (ATMPs) for the treatment of p53-deficient tumors (Gendicine and Imlygic), refractory acute lymphoblastic leukemia (Kymriah) and large B-cell lymphomas (Yescarta). In spite of these remarkable successes, immunotherapy is still associated with severe side effects for CD19+ malignancies and is inefficient for solid tumors. Controlling transgene expression through an externally administered inductor is envisioned as a potent strategy to improve safety and efficacy of immunotherapy. The aim is to develop smart immunogene therapy-based-ATMPs, which can be controlled by the addition of innocuous drugs or agents, allowing the clinicians to manage the intensity and durability of the therapy. In the present manuscript, we will review the different inducible, versatile and externally controlled gene delivery systems that have been developed and their applications to the field of immunotherapy. We will highlight the advantages and disadvantages of each system and their potential applications in clinics.es_ES
dc.description.sponsorshipSpanish ISCIII Health Research Fundes_ES
dc.description.sponsorshipEuropean Union (EU) PI12/01097 PI15/02015 PI18/00337 PI18/00330es_ES
dc.description.sponsorshipCECEyUes_ES
dc.description.sponsorshipCSyF of the Junta de Andalucia FEDER/European Cohesion Fund (FSE) for Andalusia 2016000073391-TRA 2016000073332-TRA PI-57069 PAIDI-Bio326 PI-0014-2016es_ES
dc.description.sponsorshipNicolas Monardes regional Ministry of Health 0006/2018es_ES
dc.description.sponsorshipSpanish Government FPU16/05467 FPU17/02268es_ES
dc.description.sponsorshipMCI DIN2018-010180es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media SAes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectImmunotherapy es_ES
dc.subjectGene therapy es_ES
dc.subjectExternally controlledes_ES
dc.subjectInduciblees_ES
dc.subjectAdvanced therapy medicinal products (ATMPs)es_ES
dc.subjectTransgene expressiones_ES
dc.subjectCancer es_ES
dc.subjectAutoimmunityes_ES
dc.titleExternally-Controlled Systems for Immunotherapy: From Bench to Bedsidees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3389/fimmu.2020.02044
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España